300039.SZ
Shanghai Kaibao Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.29
−4.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 1.2B | 1.5B | 1.6B | 1.1B |
| Cost of Revenue | 204.1M | 222.0M | 272.8M | 312.5M | 247.6M |
| Gross Profit | 831.2M | 930.6M | 1.2B | 1.3B | 871.3M |
| Operating Expenses | |||||
| R&D Expense | 79.7M | 88.3M | 99.8M | 95.9M | 53.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 63.5M | 69.4M | 81.5M | 81.1M | 58.6M |
| Selling & Marketing Expense | 435.4M | 493.3M | 645.6M | 777.1M | 554.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 554.7M | 627.6M | 799.3M | 928.5M | 640.2M |
| Cost and Expenses | 758.8M | 849.6M | 1.1B | 1.2B | 887.8M |
| Operating Income (EBIT) | 298.7M | 325.1M | 438.2M | 383.0M | 228.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 295.8M | 322.0M | 434.2M | 383.5M | 226.2M |
| Income Tax Expense | 37.2M | 44.0M | 59.3M | 56.6M | 36.1M |
| Bottom Line | |||||
| Net Income | 259.2M | 278.6M | 375.6M | 327.9M | 190.8M |
| Earnings from Cont. Ops | 258.6M | 278.0M | 374.9M | 326.9M | 190.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 259.2M | 278.6M | 375.6M | 327.9M | 190.8M |
| Per Share | |||||
| Basic EPS | CN¥0.25 | CN¥0.27 | CN¥0.36 | CN¥0.31 | CN¥0.18 |
| Diluted EPS | CN¥0.25 | CN¥0.27 | CN¥0.36 | CN¥0.31 | CN¥0.18 |
| Revenue Per Share | CN¥0.99 | CN¥1.10 | CN¥1.41 | CN¥1.52 | CN¥1.07 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | 360.8M | 474.6M | 420.6M | 260.1M |
| D&A | — | 35.7M | 36.3M | 37.6M | 31.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026